Hutchison China MediTech has met the primary endpoint of progression-free survival in a Phase II clinical trial for its metastatic colorectal cancer candidate fruquintinib (HMPL-013), putting it one step closer to an approval in China, according to FiercePharmaAsia.

…read more

Source: Chi-Med’s fruquintinib meets colorectal cancer PhII primary endpoint


0 No comments